As of 2025-05-14, the EV/EBITDA ratio of Coherus BioSciences Inc (CHRS) is -3.34. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CHRS's latest enterprise value is 285.92 mil USD. CHRS's TTM EBITDA according to its financial statements is -85.72 mil USD. Dividing these 2 quantities gives us the above CHRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.9x - 13.9x | 9.1x |
| Forward P/E multiples | 12.6x - 21.9x | 17.4x |
| Fair Price | (5.87) - 7.16 | (0.58) |
| Upside | -811.6% - 768.0% | -170.1% |
| Date | EV/EBITDA |
| 2025-05-13 | -3.45 |
| 2025-05-12 | -3.66 |
| 2025-05-09 | -3.58 |
| 2025-05-08 | -3.62 |
| 2025-05-07 | -3.54 |
| 2025-05-06 | -3.51 |
| 2025-05-05 | -3.66 |
| 2025-05-02 | -3.80 |
| 2025-05-01 | -3.71 |
| 2025-04-30 | -3.68 |
| 2025-04-29 | -3.63 |
| 2025-04-28 | -3.68 |
| 2025-04-25 | -3.68 |
| 2025-04-24 | -3.64 |
| 2025-04-23 | -3.81 |
| 2025-04-22 | -3.78 |
| 2025-04-21 | -3.73 |
| 2025-04-17 | -3.83 |
| 2025-04-16 | -3.64 |
| 2025-04-15 | -3.73 |
| 2025-04-14 | -3.59 |
| 2025-04-11 | -3.35 |
| 2025-04-10 | -3.20 |
| 2025-04-09 | -3.28 |
| 2025-04-08 | -3.25 |
| 2025-04-07 | -3.33 |
| 2025-04-04 | -3.26 |
| 2025-04-03 | -3.32 |
| 2025-04-02 | -3.48 |
| 2025-04-01 | -3.30 |
| 2025-03-31 | -3.31 |
| 2025-03-28 | -3.36 |
| 2025-03-27 | -3.38 |
| 2025-03-26 | -3.47 |
| 2025-03-25 | -3.56 |
| 2025-03-24 | -3.55 |
| 2025-03-21 | -3.68 |
| 2025-03-20 | -3.54 |
| 2025-03-19 | -3.47 |
| 2025-03-18 | -3.44 |
| 2025-03-17 | -3.49 |
| 2025-03-14 | -3.49 |
| 2025-03-13 | -3.45 |
| 2025-03-12 | -3.59 |
| 2025-03-11 | -3.71 |
| 2025-03-10 | -3.69 |
| 2025-03-07 | -3.69 |
| 2025-03-06 | -3.62 |
| 2025-03-05 | -3.68 |
| 2025-03-04 | -3.71 |